Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James M Rae

Showing results (1-10 of 127) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Personalized tamoxifen: what is the best way forward?James M Rae
Expert Reviews in Molecular Medicine|November 21, 2008
Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?Vered Stearns, James M Rae
Breast Cancer Research : BCR|July 13, 2006
When will tumor gene expression profiling be incorporated into clinical breast cancer decision making?Chad J Creighton, James M Rae
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2019
Pharmacogenomics and Endocrine Therapy in Breast CancerDaniel F Hayes, James M Rae
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2016
Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of UtilityDaniel L Hertz, James M Rae
Advances in Experimental Medicine and Biology|March 19, 2016
Pharmacogenetic Predictors of ResponseDaniel L Hertz, James M Rae
Breast Cancer Research : BCR|November 11, 2005
What does an orphan G-protein-coupled receptor have to do with estrogen?James M Rae, Michael D Johnson
Pharmacogenomics|June 2, 2016
One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validityDaniel L Hertz, James M Rae
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2016
Individualized Tamoxifen Dose Escalation-ResponseDaniel L Hertz, James M Rae
Breast Cancer Research and Treatment|March 5, 2004
Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitorsJames M Rae, Marc E Lippman
Pageof 13

Showing results (1-10 of 127) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Personalized tamoxifen: what is the best way forward?James M Rae
Expert Reviews in Molecular Medicine|November 21, 2008
Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?Vered Stearns, James M Rae
Breast Cancer Research : BCR|July 13, 2006
When will tumor gene expression profiling be incorporated into clinical breast cancer decision making?Chad J Creighton, James M Rae
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2019
Pharmacogenomics and Endocrine Therapy in Breast CancerDaniel F Hayes, James M Rae
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2016
Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of UtilityDaniel L Hertz, James M Rae
Advances in Experimental Medicine and Biology|March 19, 2016
Pharmacogenetic Predictors of ResponseDaniel L Hertz, James M Rae
Breast Cancer Research : BCR|November 11, 2005
What does an orphan G-protein-coupled receptor have to do with estrogen?James M Rae, Michael D Johnson
Pharmacogenomics|June 2, 2016
One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validityDaniel L Hertz, James M Rae
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2016
Individualized Tamoxifen Dose Escalation-ResponseDaniel L Hertz, James M Rae
Breast Cancer Research and Treatment|March 5, 2004
Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitorsJames M Rae, Marc E Lippman
Pageof 13